-+ 0.00%
-+ 0.00%
-+ 0.00%

GSK: 3 Key Takeaways for Long-Term Investors

The Motley Fool·11/17/2026 05:22:26
Listen to the news

Key Points

  • GSK started 18 phase 3 clinical trials in 2026.

  • Specialty medicine sales grew 15% in the third quarter.

  • Year-to-date cash generation reached GBP 7.4 billion.

On its third-quarter 2026 earnings call, held on Oct. 28, 2026, GSK (NYSE:GSK) reconfirmed its full-year 2026 guidance as sales grew 5% to GBP 8.9 billion. This commercial trajectory shows how effectively the drugmaker transitions from legacy primary-care treatments toward high-margin specialty therapies. Three things management said stand out.

1. Pipeline Acceleration Expands Late-Stage Clinical Trials

The drugmaker is accelerating its research and development (R&D) pipeline to generate long-term organic growth. It has initiated 18 phase 3 clinical trials in 2026 and expects to reach 22 by the end of the year.

Across R&D, we continue to make fantastic progress in accelerating our late-stage pipeline. ... We've now started 18 phase III studies, with a further four on track to start before the end of the year.
-- Tony Wood, Pipeline Update

2. Specialty Medicines Drive Revenue Growth and Market Share

Specialty medicines, including long-acting human immunodeficiency virus (HIV) treatments, grew 15% in the third quarter. These higher-margin therapies offset broader price pressures across the inhaler market.

Commercial momentum continued in the Q3, driven mainly by specialty medicines, up 15%. ... Cabenuva remains the only long-acting injectable regimen for HIV treatment, establishing a strong foundation with patients who prefer to take medicines less frequently.
-- Nina Mojas, Growth Drivers

3. Restructuring Program Reallocates Capital to Core Assets

Management launched the Accelerate Growth program to streamline support operations and supply chain logistics. The program redirects savings toward late-stage drug development while maintaining operating profit margins.

Operating profit grew 5%, with the margin broadly stable, as increased R&D investment was broadly offset by cost of goods and SG&A productivity as we further match our cost base to the evolving portfolio.
-- Julie Brown, Financial Performance

Looking Ahead

Operating momentum in specialty launches positions the business well for full-year performance. Structural advantages in long-acting HIV regimens and expanded oncology indications provide lasting pricing power, while management tracks pricing discipline across respiratory lines.

Looking ahead, we remain on track to deliver our full year 2026 guidance. Sales are expected in the upper half of the range, driven by specialty performance.
-- Julie Brown, Financial Performance

Long-term value creation relies on executing this accelerated development program while maintaining strict cost control.

To close, we remain focused on executing our strategy, which is built on driving top-line growth, building and accelerating the late-stage portfolio, and actively reallocating resources to where they can create the largest value for patients and shareholders.
-- Luke Miels, Chief Executive Officer

The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.